Sunitinib Malate Market
Sunitinib Malate Global Strategic Business Report 2024-2030: Emerging Clinical Trials for Combination Therapies Propels Competitiveness
November 11, 2024 11:04 ET | Research and Markets
Dublin, Nov. 11, 2024 (GLOBE NEWSWIRE) -- The "Sunitinib Malate - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Sunitinib Malate...
Global Kidney Cancer Drugs Market
Global Kidney Cancer Drugs Market Research Report 2023: Forecasts to 2027 & 2032 with Focus on Axitinib (Inlyta), Cabozantinib (cabometyx), and Pazopanib
March 13, 2023 08:53 ET | Research and Markets
Dublin, March 13, 2023 (GLOBE NEWSWIRE) -- The "Kidney Cancer Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.The global kidney cancer drugs market will...
Global Kidney Cancer Drugs Market
Global Kidney Cancer Drugs Market Report 2022-2026 & 2030 - Focus on Immunotherapy, Chemotherapy and Targeted Therapy
April 19, 2022 04:48 ET | Research and Markets
Dublin, April 19, 2022 (GLOBE NEWSWIRE) -- The "Kidney Cancer Drugs Global Market Report 2022, Type, Product, End Users" report has been added to ResearchAndMarkets.com's offering. The global...
Global Kidney Cancer Drugs Market
Kidney Cancer Drugs Industry Assessment and Recovery to 2030 - Insights on Drugs, Trends, Global Market Shares, Competitors, Strategies and More
February 04, 2022 04:38 ET | Research and Markets
Dublin, Feb. 04, 2022 (GLOBE NEWSWIRE) -- The "Kidney Cancer Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering. The...
GB nlogo.png
Graybug Vision to Participate in the American Academy of Ophthalmology 2021 Annual Meeting
November 01, 2021 07:30 ET | Graybug Vision, Inc.
BALTIMORE, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
22157.jpg
Global Kidney Cancer Diagnostics and Therapeutics Market (2020 to 2026) - Featuring Abbvie, Active Biotech and AstraZeneca Among Others
August 05, 2021 07:53 ET | Research and Markets
Dublin, Aug. 05, 2021 (GLOBE NEWSWIRE) -- The "Global Kidney Cancer Diagnostics and Therapeutics Market 2020-2026" report has been added to ResearchAndMarkets.com's offering. The global kidney...
GB nlogo.png
Graybug Vision Reports Preliminary Topline Results from Phase 2b ALTISSIMO Trial
March 09, 2021 07:30 ET | Graybug Vision, Inc.
Median time to first supportive therapy was 5 months for GB-102 1mg48% of patients in the GB-102 1 mg arm were rescue-free for at least 6 monthsControl of retinal thickness was consistent across all...
GB nlogo.png
Graybug Vision Announces Full Year 2020 Financial Results and Recent Corporate Developments
March 04, 2021 17:04 ET | Graybug Vision, Inc.
REDWOOD CITY, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the...
GB nlogo.png
Graybug Vision to Participate in SVB Leerink Global Healthcare Conference
February 17, 2021 07:30 ET | Graybug Vision, Inc.
REDWOOD CITY, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...
GB nlogo.png
Graybug Vision Appoints Bettina Maunz as Chief People Officer, Expanding the Company’s Executive Team
February 01, 2021 07:30 ET | Graybug Vision, Inc.
REDWOOD CITY, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...